Breadcrumb
Dean's List: New Funding Awards 2022
New Funding Awards
2022
December 2022
New Federal Awards
Gordon Buchanan | Neurology | NIH R01 - 5 years | Serotonergic circuit mechanisms in postictal recovery and arousal |
Kamal Rahmouni | Neuroscience & Pharmacology | NIH R01 - 4 years | Role of FGF21 Action in Hypothalamic Neurons in Obesity-Associated Hypertension |
Rainbo Hultman | Molecular Physiology & Biophysics | NIH R25 - 4 years | Iowa-Diversifying Research And Mentorship (iDREAM) |
Yuriy Usachev | Neuroscience & Pharmacology | NIH R01 - 5 years | Novel Circuits and Mechanisms of Descending Pain Modulation |
Competitive Awards
Barcey Levy | Family Medicine | Duke Clinical Research Institute | Iowa UH3 Subaward Low Back Pain Clinical Coordinating Center (IMPACt-LBP CCC) |
Other Awards
Ali Jabbari | Dermatology | Pfizer Global Research & Development | A study of RYZ101 compared with standard of care therapy in subjects with SSTR+ and GEP-NET that has treatment with 177Lu-DOTATATE/TOC. |
David Bushnell | Radiology | RayzeBio, Inc. | A study of RYZ101 compared with standard of care therapy in subjects with SSTR+ and GEP-NET that has treatment with 177Lu-DOTATATE/TOC. |
David Elliott | Internal Medicine | IQVIA RDS Inc. | A Phase 2 Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet |
Mohammad Bashir | Cardiothoracic Surgery | CytoSorbents Corporation | Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D) Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) |
Nicholas Mohr | Emergency Medicine | University of California, Los Angeles | EMERGEncy ID NET: Preventing Emerging Infections through Vaccine Effectiveness Testing II-COVID (PREVENT II)Data Coordinating Center & Supplement |
Saima Sharif | Internal Medicine | CTI Clinical Trial Services, Inc. | A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma |
Spyridon Fortis | Internal Medicine | AstraZeneca Pharmaceuticals LP | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) |
Usha Perepu | Internal Medicine | Medpace Clinical Research, LLC | A phase 3 study of the Hepcidin Mimetric Rusfertide (PTG-300) in patients with Polycythemia Vera. |
New Federal Awards
Don Anderson | Orthopedics | AHRQ R18 – 5 years | Integrating Next Generation Simulator Training and Operating Room Performance Assessment into Orthopedic Residency Programs |
Mariah Hassert | Pathology | NIH F32 – 2 years | Antiviral lung resident memory T-cell maintenance and reinvigoration |
Alison Lynch | Psychiatry | SAMHSA H79 – 5 years | Recovery and Empowerment to Combat Opioids delivered by telehealth and collaboration across Iowa (RECOVER-IA) |
Scott Moye-Rowley | Physiology | NIH R21 – 2 years | Chemical genetic analysis of Candida glabrata CDR1 expression |
Amy Ryan | Anatomy & Cell Biology | NIH R01 (Transfer) – 5 years | Characterization of mechanisms regulating multiciliated cell specification using patient-specific induced pluripotent stem cells |
Hanora Van Ert | Microbiology | NIH F32 – 2 years | Determining Tropism and Mechanisms of Ebola Virus Entry in Placental Tissues |
Competitive Awards
Michael Shy | Neurology | Charcot-Marie- Tooth Association | The virologic efficacy of REGN10933+REGN10987 across different dose regimens in outpatients with SARS-CoV-2 |
Other Awards
Sabarish Ayyappan | Internal Medicine | Genmab US Inc. | Safety and Efficacy of GEN3009 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
Gordon Buchanan | Neurology | Cure Epilepsy | 960831 Nighttime mechanisms for SUDEP |
Joseph Caster | Radiation Oncology | DeGregorio Family Foundation | Manipulating redox metabolism with pharmacologic ascorbate and superoxide dismutase mimetics to enhance the efficacy of chemoradiation for locally advanced esophageal adenocarcinoma. |
Joseph Dillon | Internal Medicine | Crinetics Pharmaceuticals | A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome. |
Janet Fairley | Dermatology | AstraZeneca Pharmaceuticals LP | Maintenance of pluripotency in ferret to evaluate autologous cell therapy |
Umar Farooq | Internal Medicine | Arsenal Biosciences | A phase-one study to evaluate the safety and efficacy of AB-1015 in patients with platinum-resistant epithelial ovarian cancer |
Nicole Fleege | Internal Medicine | ASCO Foundation | 2020 Conquer Cancer - Rising Tide Foundation for Clinical Cancer Research Career Pathway Grant in Symptom Management |
David Gordon | Pediatrics | Hyundai Hope on Wheels | 990458 Targeting Impaired Differentiation in Ewing Sarcoma Tumors |
Mohammed Milhem | Internal Medicine | PHILOGEN S.p.A. | Study of The Efficacy of Daromun Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patient |
Nicholas Mohr | Emergency Medicine | Vanderbilt University Medical Center | COVID: Adult Inpatient SARS-CoV-2 Vaccine Effectiveness Surveillance (IVY 5) |
Amy Ryan | Anatomy & Cell Biology | Cystic Fibrosis Foundation | Maintenance of pluripotency in ferret to evaluate autologous cell therapy |
New Federal Awards
Masaaki Kurahashi | Internal Medicine | NIH R01 - 2 years | Inhibitory mechanisms of PDGFRa+ interstitial cells in gastrointestinal motility |
Bing Li | Pathology | NIH R01 - 2 years | Immunomodulatory mechanisms of E-FABP in psoriasis pathogenesis |
Nandakumar Narayanan | Neurology | NIH P20 - 2 Years | Prefrontal Cortex, Cognition, and Speech Symptoms in PD (PRECIS-PD) |
Jennifer Power | Dermatology | DoD, CDMRP - 3 Years | ME200128 - Establishing the Role of Deployments in Melanoma in the Military |
Andrea Weber, Contact PI Joshua Radke, MPI | Psychiatry and Emergency Medicine | SAMHSA H79 - 3 Years | Training Expansion in Addiction Medicine and Medications for Addiction Treatment at the University of Iowa (TEAM-MAT-UI) |
Other Awards
Chandrikha Chandrasekharan | Internal Medicine | Merck Sharp & Dohme Corp. | A Phase 2 Study to Evaluate the Efficacy and Safety of MK-6482 Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET) |
Umar Farooq | Internal Medicine | Artiva Biotherapeutics, Inc. | A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin |
Mony Fraer | Internal Medicine | Covance, Inc. | A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients with Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease |
Huy Tran | Internal Medicine | Exact Sciences Corporation | ALTUS: PERFORMANCE OF A MULTI-TARGET HEPATOCELLULAR CARCINOMA (HCC) TEST IN SUBJECTS WITH INCREASED RISK |
Competitive Renewal
William Sivitz | Internal Medicine | Case Western Reserve University | Epidemiology of Diabetes Interventions and Complications (EDIC) |
New Federal Awards
Chih-Jen Cheng | Internal Medicine | NIH R01 - 5 years | Exploring the pathogenesis of classic Bartter syndrome |
Dao-Fu Dai | Pathology | NIH R01 - 5 years | Metabolic reprogramming and FGF21 signaling in kidney health and polycystic kidney diseases |
John Engelhardt | Anatomy and Cell Biology | NIH C06 - 5 years | National Ferret Research and Resource Institute (NFRRI) at University of Iowa |
Carl Andrew Frank | Anatomy and Cell Biology | NIH R01 - 5 years | How discrete homeostatic signals stabilize synapse function across time. |
Zizhen Kang | Pathology | NIH R21 - 2 years | Understanding the role of LRRK2 G2019S-mediated gut-brain axis in the pathogenesis of Parkinson's disease |
Vincent Magnotta | Radiology | NIH R01 - 5 years | Suicidality in Bipolar and Major Depression Disorders |
Wendy Maury Steven Varga | Microbiology | NIH UH2 - 2 years | Elucidating mechanisms of interferon gamma that protect against Ebola virus infection |
Seongjin Seo | Opthamology and Visual Sciences | NIH R01 - 4 years | Compartmentalized protein localization in photoreceptors |
Ryan Zander | Microbiology | NIH R00 - 2 years | Defining the transcriptional, phenotypic, and functional heterogeneity of virus specific CD4 T cells during chronic viral infection |
Qiang Zhang | Neurology | NIH R03 - 2 years | Glycolysis and Alzheimer's Disease |
Other Awards
Chris Ahern | Molecular Physiology & Biophsyics | hC Bioscience, Inc. | hC Bioscience |
Ferhaan Ahmad | Internal Medicine | AavantiBio Cytokinetics, Inc. | Ahmad/AAvantiBio-Gene Therapy For Inherited Dilated Cardiomyopathy (DCM) Trial to Evaluate the Efficacy and Safety of CK3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction |
Michael Anderson | Molecular Physiology & Biophysics | BrightFocus Foundation | Testing the Influence of Podosomes on Intraocular Pressure |
Linda Cadaret | Internal Medicine | Acceleron Pharma, Inc. | ZENITH |
Michael Ciliberto | Pediatrics | PPD Investigator Services, LLC | Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2) |
Bruce Gantz | Otolaryngology Head Neck Surgery | Cochlear Americas | Investigation to evaluate the safety and effectiveness of cochlear implantation in children and adults with unilateral hearing loss/single-sided deafness |
Marlan Hansen Matthew Howard Samuel Young | Otolaryngology Head Neck Surgery Neurosurgery Anatomy and Cell Biology | AskBio | Recombinant AAV capsid library screening to identify clinically relevant capsid variants in humans |
Sarat Kuppachi | Internal Medicine | CSL Behring L.L.C. | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients |
Katherine Mathews | Pediatrics | Edgewise Therapeutics, Inc. | EDG-5506-201 Medpace - EDG-5506-201: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy |
Varun Monga | Internal Medicine | ADC Therapeutics | A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patient |
Michael Shy | Neurology | Charcot-Marie-Tooth Association | CMT2F Biomarkers and Outcome Measures |
Yousef Zakharia | Internal Medicine | AstraZeneca AB | A Phase I/IIa First-in-human, Open-label, Modular Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours |
Competitive Renewal
Craig Ellermeier | Microbiology | NIH R01 - 4 years | Identification of daptomycin resistance mechanisms in Clostridioides difficile |
Chou-Long Huang | Internal Medicine | NIH R01 | WNK kinase cascade in health and disease |
Robert Piper | Molecular Physiology & Biophysics | NIH R01 | Ubiquitin-dependent sorting in endosomes and the TGN |
New Federal Awards
Stephen Baek | Radiation Oncology | DoD, Army - 1 year | Microstructure-aware Reaction Models for PBXs in the Weak-to-Moderate Shock Regime |
Valentina Botero | Neuroscience & Pharmacology | NIH F31 - 2 years | Neuronal mechanisms of neurofibromin-mediated modulation of metabolic homeostasis |
Amy Conrad | Pediatrics | NIH R56 - 1 year | Brain Development and Pre-Speech Function in Infants with Isolated Oral Clefts: Relationship to Anesthesia Exposure and Oxygenation |
Mark Greiner | Opthamology and Visual Sciences | NIH R21 - 2 years | Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy |
James Holmes | Radiology | NIH R01 - 5 years | Simultaneous MRI/US for real-time liver ablation guidance and confirmation |
Bing Li | Pathology | NIH U01 - 5 years | Determine the molecular and metabolic mechanisms by which A-FABP links dysregulated lipid metabolism-induced obesity/breast cancer risk |
Nathaniel Mullin | Inst for Vision Research | NIH R21 - 2 years | Pathogenesis of Mitochondrial Retina Disease |
Amy Ryan | Anatomy and Cell Biology | NIH R01 (Transfer) - 3 years & 1 year | Characterization of mechanisms regulating multiciliated cell specification using patient-specific induced pluripotent stem cells Quantitative analysis of mucociliary clearance in airway ciliopathies |
Miranda Schene | Molecular Physiology & Biophysics | NIH F03 - 4 years | Using a Molecular Toolkit to Examine Potassium Channel Gating and Regulation |
Kristina Thiel | OBGyn | NIH K22 - 3 years | Attacking aggressive p53 mutants in gynecologic cancer |
Budd Tucker | Opthamology and Visual Sciences | NSF - 4 years | Collaborative Research: RECODE: Microfluidic and genetic technologies to direct and select retinal cell types from human induced pluripotent stem cell-derived retinal organoids |
Andrea Weber | Psychiatry | HRSA H79 - 3 years | Longitudinal Integration and Virtual Expansion of Rural Substance Use Disorder and Liver Disease Treatment in Iowa (LIVER-SUD-IA) |
Jason Wilken | Physical Therapy & Rehab Sciences | DoD, CDMRP - 2 years | OP210037 - Carbon Fiber Orthosis Cuff Design |
Lok-Yin Roy Wong | Microbiology | NIH K99 - 2 years | Phenotypic and functional characterization of Betacoronavirus Internal protein in relation to virulence |
Ling Yang | Anatomy and Cell Biology | NIH R01 - 4 years | Role of ADH5 in the Regulation of Brown Adipose Tissue Metabolic Homeostasis |
Other Awards
Umar Farooq | Internal Medicine | Syneos Health, LLC | A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta () T Cells in Adults with B-Cell Malignancies. |
Douglas Fredericks | Orthopaedic Surgery | Surgentec | EFFICACY OF SURGENTEC BONE PUTTY AS A BONE VOID FILLER IN A RABBIT METAPHYSEAL DEFECT MODEL |
Margarida Magalhaes-Silverman | Internal Medicine | Medspace Clinical Research, LLC | A randomized, double-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy |
Katherine Mathews | Pediatrics | Capricor Therapeutics | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF HUMAN ALLOGENEIC CARDIOSPHERE-DERIVED CELLS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (HOPE-3) |
Delwyn Miller | Psychiatry | University of Southern California/NIH | Long-Term Nicotine Treatment of Mild Cognitive Impairment |
Sneha Phadke | Internal Medicine | AstraZeneca Pharmaceuticals LP | A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients wi |
Michael Shy | Neurology | Applied Therapeutics, Inc. | Clinical Trial - SORD Study AT-007-1005 |
Grerk Sutamtewagul | Internal Medicine | Novartis Corporation | A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase |
Elizabeth Takacs | Urology | Medtronic, Inc. | TITAN 2 |
Yousef Zakharia | Internal Medicine | Bristol-Myers Squibb Company | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma |
Competitive Renewal
Marlan Hansen | Otolaryngology | NIH T32 - 5 years | Research Training Program in Otolaryngology |
New Federal Awards
Gail Bishop | Microbiology and Immunology | NIH R01 - 4 years | Regulation of B cell signaling in autoimmunity by TRAF3 |
David Kaczka | Anesthesia | DoD, CDMRP - 3 years | Preclinical Evaluation of Multi-Frequency Oscillatory Ventilation in a Large Animal Model of Acute Respiratory Failure |
Damian Krysan | Pediatrics | NIH R01 - 5 years | Discovery and development of antifungal acetyl CoA synthetase inhibitors |
George Richerson | Neurology | NIH R01 - 5 years | Prevention of SUDEP by milk whey: Role of CO2 chemoreception and serotonin |
Rasna Sabharwal | Internal Medicine | NIH 1 R21 - 2 years | RAS-Driven Central Inflammation and Cognitive Decline with Aging. |
Dong Rim Seol | Orthopaedics and Rehabilitation | NIH R03 - 2 years | Exosome-based Cell Homing and Lineage-Specific Differentiation Strategies for Dental Pulp Regeneration |
Douglas Spitz Val Sheffield | Radiation Oncology | NIH R21 - 2 years | Evaluation of Orthogonally Oriented Electromagnetic Fields to Stabilize ROS, Induce DNA damage and Improve Survival in Non-Small Cell Lung Cancer |
Michael Wright | Molecular Phyusiology and Biophysics | NIH 1 R01 - 4 years | Construction of the Androgen Receptor Interactome: A Molecular Framework for Probing Genetic Interactions in Androgen-Dependent Signaling |
Other Awards
Muhammad Furqan | Internal Medicine | PPD Investigator Services, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinu |
Nabeel Hamzeh | Internal Medicine | Genentech, Inc | A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis |
Sharon Larson | Surgery | CryoLife, Inc | A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with and On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban |
Katherine Mathews | Pediatrics | FIbroGen, Inc | A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in ambulatory subjects with Duchenne Muscular Dystrophy (DMD |
Sidakpal Panaich | Internal Medicine | Edwards Lifesciences, LLC | Edwards PASCAL CLASP II TR Pivotal Clinical Trial |
Patricia Winokur | Internal Medicine | Pfizer, Inc | A Study to Evaluate Additional Dose(s) of BNT162b2 in Healthy Individuals Previously Vaccinated With BNT162b2 |
Competitive Renewal
Evan Abel Andrew Norris | Internal Medicine Pediatrics | NIH T32 - 5 years | Diabetes Research Training Program |
John Engelhardt | Anatomy and Cell Biology | NIH R01 - 4 years | Biology of submucosal gland stem cells in the airway |
Yumi Imai | Internal Medicine | NIH R01 - 4 years | Role of lipid droplet proteins in islet function in diabetes and obesity |
Alison Lynch | Psychiatry | HRSA D40 - 3 years | Graduate Psychology Training in Integrated Mental Health and Substance Use Treatment for Rural Iowa Youth |
New Federal Awards
Toshihiro Kitamoto George Richerson | Anesthesia Neurology | NIH R21 - 2 years | Effects of dietary alpha-linolenic acid on SUDEP, seizures, and neural structure and function in mouse models of epilepsy |
Jessica Skeie | Ophthalmology | NSF - 1 year | I-Corps: Novel Antioxidant Ocular Therapeutic |
Other Awards
Don Anderson | Orthopedics | Stryker Orthopaedics | Mechanical Tradeoffs in Implant Design, Implantation Choices, Impingement-Free Range of Motion, Joint Stability, Muscle Force Requirements, and Subluxation Risk After Reverse Shoulder Arthroplasty with the Stryker/Tornier Perform System |
Lovkesh Arora | Anesthesia | Edwards Lifesciences LLC | HPI SMART- BP Trial: Hypotension Prediction Index Software Guided Hemodynamic Management for Noncardiac Surgery Patients - Blood Pressure Trial |
Linda Cadaret | Internal Medicine | Acceleron Pharma, Inc. | A Phase 3, Randomized, Double-blind, Placebo controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients (HYPERION) |
Chandrikha Chandrasekharan | Internal Medicine | Novartis Corporation | A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Daniel Diekema | Internal Medicine | bioMerieux, Inc. | First in Human Phase 1 /2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors |
Mohammed Milhem | Internal Medicine | Checkmate Pharmaceuticals | VITEK Evolution Compact Instrument Clinical Trial, and Reproducibility Data Collection for VITEK 2 Instrument Protocol |
Brad Dixon | Internal Medicine | Bayer HealthCare Pharmaceuticals Inc. | A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kid |
Umar Farooq | Internal Medicine | Janssen Research & Development, Inc. | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) |
Yusuf Menda | Radiology | Clovis Oncology, Inc. Fusion Pharmaceuticals, Inc. | A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants with FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours |
Brendan Patterson | Orthopedics | Stryker Orthopaedics | Mechanical Tradeoffs in Implant Design, Implantation Choices, Impingement-Free Range of Motion, Joint Stability, Muscle Force Requirements, and Subluxation Risk After Reverse Shoulder Arthroplasty with the Stryker/Tornier Perform System |
Antonio Sanchez | Internal Medicine | Boehringer Ingelheim Pharmaceuticals, Inc. | Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 weeks treatment in patients with clinically significant |
Michael Willey | Orthopedics | Excere Medical LLC | Bispectral EEG in Early Detection/Prediction of Delirium (Phase 1 Device Validation) |
Yousef Zakharia | Internal Medicine | Merck Sharp & Dohme LLC | A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC |
Competitive Renewals
Kathleen Sluka Yuriy Usachev | Physical Therapy Neuroscience & Pharmacology | NIH T32 - 5 years | Interdisciplinary Training Program in Pain Research |
New Federal Awards
Alejandro Pezzulo | Internal Medicine | NIH R01 - 5 years | Epigenetic mechanisms of inflammatory memory propagation in human airway epithelia |
Allan Anderson Robert Philibert | Psychiatry | NIH R21 - 2 years | Predicting Alcohol Withdrawal using DNA Methylation |
Dong Rim Seol | Orthopedics | NIH R21 - 2 year | Preventive and Therapeutic Effects of Bone Marrow Stem Cell-Derived Exosomes on Spine Dural Fibrosis |
Erica Gansemer | Orthopedics | NIH F32 - 1 year | The role of NADPH production in regulating endoplasmic reticulum function and the progression of non-alcoholic steatohepatitis |
Hasem Habelhah | Pathology | NIH R01 - 5 years | The roles of TRAF2 and RIP1 in breast cancer cell survival |
Samuel Young | Anatomy & Cell Biology | NIH R03 - 1 year | Elucidating the roles of CACNA2D2 and CACNA2D3 in presynaptic regulation of mammalian synaptic function |
Stefan Strack | Neuroscience & Pharmacology | NIH T32 - 5 years | Predoctoral Training in the Pharmacological Sciences |
Other Awards
Alejandro Pezzulo | Internal Medicine | Ann Theodore Foundation | Personal Response Profiles in Sarcoidosis |
Chandrikha Chandrasekharan | Internal Medicine | Syros Pharmaceuticals | A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors |
Janice Staber | Pediatrics | Saliogen Therapeutics, Inc. | Gene Coding Therapy for Hemophilia A |
Manasa Nayak | Internal Medicine | American Heart Association | 942168 Novel role of Pyruvate Kinase M2 in experimental Deep Vein Thrombosis |
Mel Sharafuddin | Surgery | Endologix, Inc. | JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization |
Michael Ciliberto | Pediatrics | Stoke Therapeutics, Inc. | An Open-Label Extension Study for Patients with Dravet Syndrome who Previously Participated in Studies of STK-001 |
Michael Wall | Opthamology | Invex Therapeutics, Inc. | Consulting Agreement with Invex Therapeutics, Ltd |
Micahel Welsh | Internal Medicine | Edward N. & Della L. Thome Memorial Foundation | Developing Novel Agents that Enhance Energy Metabolism for Alzheimer's Disease |
Mohammed Milhem | Internal Medicine | BicycleTX Limited | Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies |
Rohan Garje | Internal Medicine | PSI Pharma Support America, Inc. | SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177Lu- |
Santiago Ortega Gutierrez | Neurology | Stryker Neurovascular | Safety and Efficacy Assessment of Surpass EVOLVE (SEASE) Study |
Sean Fain | Radiology | Genetech, Inc. | 129Xe MRI Assessment Of Disease Progression In Patients With Chronic Obstructive Pulmonary Disease Treated With Standard-Of-Care Medications With Or Without Daily Open-Label Azithromycin Treatment To Prevent Acute Exacerbation |
Competitive Renewals
Jack T. Stapleton | Internal Medicine | HRSA H76 - 3 years | OP EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE |
New Federal Awards
Budd Albert Tucker Edward M. Stone Robert F. Mullins | Ophthamology | NIH FO1 | A Next Generatoion Outer Retinal Microphysiological System |
David A. Stoltz Lynda Spencer Ostedgaard | Internal Medicine | NIH R01 - 4 years | Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health |
Joseph Vecchi | Molecular Physiology | NIH F31 - 2 years | Feature characteristics and signaling mechanisms involved in SGN neurite guidance by engineered topographical and biochemical micropatterns |
Grant Donald Brown Nicholas Matthew Mohr Santiago Gutierrez | Biostatistics | NIH R01 - 5 years | Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health |
Sheila Annetta | Biochemistry | NIH R21 - 2 years | In vivo metabolic labeling of photoreceptor proteins |
Other Awards
Alejandro Comellas | Internal Medicine | Laurent Pharmaceuticals, Inc. | RESOLUTION: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II STUDY OF THE EFFICACY AND SAFETY OF LAU-7b IN THE TREATMENT OF ADULT HOSPITALIZED PATIENTS WITH COVID-19 DISEASE_Phase2 |
Daniel James Diekema | Internal Medicine | bioMerieux, Inc. | VITEK 2 and VITEK 2 Compact GN24 Antimicrobial Susceptibility Tests |
Eric Alfred Hoffman | Radiology | Trustees of Columbia University | Precision phenotyping of emphysema in the elderly: the MESA Lung Study |
Hanna Dominika Zembrzuska | Internal Medicine | AbbVie, Inc. | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti- |
Huy T T Tran
| Internal Medicine | Pharmaceutical Research Associates
| A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of live |
Jon Michael Resch | Neuroscience & Pharmacology | American Heart Association | The basis for aldosterone-mediated activation of hindbrain NTS Hsd11b2 neurons |
Kathleen E. Dlouhy | Neurosurgery | Medtronic, Inc. | EMBOLIZATION OF THE MIDDLE MENINGEAL ARTERY WITH ONYXTM LIQUID EMBOLIC SYSTEM IN THE TREATMENT OF SUBACUTE AND CHRONIC SUBDURAL HEMATOMA (EMBOLISE) STUDY |
Paul B. McCray | Pediatrics | Spirovant Sciences, Inc. | LV-mediated ABCA3 gene expression for correction of the ABCA3 deficiency phenotype |
Qian Shi | Internal Medicine | American Heart Association | Novel role of Insulin receptor substrate 2 (IRS2) in the maintenance of calcium homeostasis in the heart |
Rohan Garje | Internal Medicine | Exelixis, Inc. | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors |
Sean B. Fain | Radiology | Duke University | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis |
Tracey A. Cho | Neurology | Massachusetts General Hospital | NeuroNEXT Clinical Trial: A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease |
Varun Monga | Internal Medicine | Trillium Therapeutics Inc. | A Phase I/II Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma |
Umar Farooq | Internal Medicine | FATE Therapeutics | A Phase I Study of FT819 in Subjects with B-cell Malignancies |
Xingshen Sun | Anatomy & Cell Biology | Emily's Entourage | Therapeutic Utility of DNP for Cystic Fibrosis using MP-101 compound in ferrets |
Yousef Zakharia | Internal Medicine | Castle Biosciences, Inc. Pfizer, Inc. | Prognostic Gene Expression Profiling and Adjuvant Therapy in Stage IIIA-B Cutaneous Melanoma (PERSONALize) Phase 1 of escalating doses of Seleno-L-methionine (SLM) in sequential combination with a fixed doses and schedule of axitinib and pembrolizumab(SAP) in untreated patients with clear cell Renal Cell Carcinoma (ccRCC) |
New Federal Awards
Jon Houtman Steven Varga | Microbiology and Immunology | NIH R21 - 2 years | CD4 T cell intrinsic signaling defects during viral exhaustion |
Nandakumar Narayanan | Neurology | NIH R01 - 5 years | VTA dopamine neurons and cognitive symptoms of Parkinson's |
Adam Mailloux | Microbiology and Immunology | NIH R21 - 1 year | Autohistomagnetic Isolation of Tumor-reactive T-cells |
Craig Ellermeier | Microbiology and Immunology | NIH R21 - 2 years | Regulation of the C. difficile cell envelope by Two-component systems |
Alexander Boyden | Pathology | NIH R21 - 2 years | Role of B cell interactions in CNS autoimmune demyelination |
Claudia Mello-Thoms | Radiology | NIH R01 - 5 years | Satisfaction of Search in Breast Cancer Detection |
Philip Polgreen | Internal Medicine | NIH R01 - 5 years | Estimating the risk for and severity of respiratory infections attributable to CFTR hterozygosity |
Prajwal Gurung | Internal Medicine | NIH R01 - 5 years | Implicating a previously unknown Dectin1-RIPK2-CARD9 signaling in providing resistance against Leishmania major infection |
Pamela Geyer | Biochemistry and Molecular Biology | NIH R21 - 2 years | Aging and the nuclear lamina in mitotic stem cells |
Other Awards
Chris Ahern | Molecular Phyusiology and Biophysics | University of Wisconsin-Madison | Restoring vision with high-fidelity nonsense codon correction |
Sabarish Ayyappan | Internal Medicine | Genmab US Inc | A Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma |
Sabarish Ayyappan | Internal Medicine | Regeneron Pharmaceuticals, Inc | A study to assess the anti-tumor activity and safety of regn1979, an anti-cd20 x anti-cd3 bispecific antibody, in patients with relapsed or refractory b-cell non-Hodgkin lymphoma |
Linda Cadaret | Internal Medicine | Gossamer Bio, Inc | Evaluating the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH) |
John Engelhardt | Anatomy and Cell Biology | Cystic Fibrosis Foundation | Development of Cystic Fibrosis Models in the Ferret |
Muhammad Furqan | Internal Medicine | Inhibrx, Inc | A Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors |
Nicholas Mohr | Anesthesia | Vanderbilt University Medical Center | COVID: Adult Inpatient SARS-CoV-2 Vaccine Effectiveness Surveillance |
Varun Monga | Internal Medicine | Pfizer, Inc | A trial evaluating pharmacokinetics, safety and efficacy of pf 07284890 (arry 461) in participants with BRAF v600 mutant solid tumors with and without brain involvement |
Douglas Van Daele | Otolaryngology | Nyxoah SA | Assessing the safety and effectiveness of the GenioTM dual-sided hypoglossal nerve stimulation system for the treatment of obsructive sleep apnea in adult subjects (DREAM) |
New Federal Awards
Jordan Schulz | Psychiatry | NIH K23 - 5 years | Autonomic Dysfunction as Early Pathologic Feature of Huntington's Disease |
Ron Weigel Tiandao Li Junlin Liao | Surgery | DoD, CDMRP - 3 years | SUMO Inhibition Represses Mammary Oncogenesis Through Etv1 |
Other New Awards
Camille Dunn-Johnson | Otolaryngology | MED-EL Corporation | Single-Sided Deafness and Asymmetric Hearing Loss |
John Engelhardt | Anatomy and Cell Biology | Cystic Fibrosis Foundation | Regenerative Properties of Airway Submucosal Gland Stem Cell Niches |
Douglas Laux | Internal Medicine | Replimune, Inc | Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaeneous squamous cell carcinoma |
Enrique Leira | Neurology | Massachusetts General Hospital | StokeNet: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY) |
Varun Monga | Internal Medicine | Medical College of Wisconsin | Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as having CDK Pathway Alteration (BOAST) |
Muhammad Furqan | Internal Medicine | Hoosier Cancer Research Network, Inc | Chemo-immunotherapy Followed by Combo of Durvalumab and ATRi in Treatment Naïve Patients with Extensive Stage Small Cell Lung Cancer |
Muhammad Furqan | Internal Medicine | Bristol-Myers Squibb Company | First-in-human of BMS-986258 Alone and in Combo with Nivolumab in Advanced Tumors |
Muhammad Furqan | Internal Medicine | Aprea Therapeutics | APR-246 in Combination with Pembrolizumab in Subjects with Solid Tumor Malignancies |
Lucy Wibbenmeyer | Surgery | Avita Medical Americas, LLC | Regenerative Epidermal Suspension Prepared with the RECELL Device Compared to Standard of Care Dressings for Treatment of Partial |
Pat Winokur | Internal Medicine | Sanofi Pasteur, Inc | Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older |
January 2022
Jennifer Bermick | Pediatrics | NIH R01 transfer - 5 years | Targeting iron to improve outcomes in neonatal Escherichia coli sepsis |
Zizhen Kang | Pathology | NIH R01 transfer - 2 years | Integration of IL-17 and notch signaling in the pathogenesis of CNS inflammation |
Stanely Perlman | Microbiology and Immunology | NIH T32 - 5 years | Training in Molecular Virology, Viral Pathogenesis and Viral Vectors |
Jon Resch | Neuroscience and Pharmacology | NIH R00 - 3 years | Central Regulation of sodium appetite via synergistic action of RAAS-sensitive neurons |
Shunguang Wei | Internal Medicine | NIH R01 - 4 years | Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure |
Other Awards
Alejandro Comellas | Internal Medicine | Regeneron Pharmaceuticals, Inc | The virologic efficacy of REGN10933+REGN10987 across different dose regimens in outpatients with SARS-CoV-2 |
Muhammad Furqan | Internal Medicine | PPD Investigator Services, LLC | Autologous T-Cells expressing enhanced TCRs specific for NY-ESO-1/LAGE-1a alone or in combo with pembrolizumab |
Margarida Magalhaes-Silverman | Internal Medicine | Marker Therapeutics, Inc | Donor-derived multi-tumor-associated antigen-specific T Cells administered to patients with AML following hematopoietic stem cell transplantation |
Philip Polgreen | Internal Medicine | University of Maryland | Gathering new contact network data to inform interventions designed to Decrease the Spread of COVID-19 |
Antonio Sanchez | Internal Medicine | Merck Sharp & Dohme Corp | Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis |